CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself. Innovation is at the heart of everything we do. It is reflected in our creation of state of the art plasma collection and manufacturing facilities, our investment in improving current therapies, finding new indications for existing therapies, and innovating new therapeutic products for unmet needs
Quote | CSL Ltd ADR (OTCMKTS:CSLLY)
Last: | $101.20 |
---|---|
Change Percent: | -1.33% |
Open: | $101.51 |
Close: | $101.20 |
High: | $102.1 |
Low: | $101.03 |
Volume: | 22,487 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | CSL Ltd ADR (OTCMKTS:CSLLY)
2024-06-25 12:31:58 ET More on CSL CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL Divi...
2024-06-21 15:50:11 ET Summary Haemonetics faces near-term revenue growth challenges due to the loss of its plasma collections business with CSL over the next two years. Management has used M&A to boost its revenue growth, including the very successful deal for Cardiva to ente...
Message Board Posts | CSL Ltd ADR (OTCMKTS:CSLLY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza PR Newswire CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response...
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These res...
Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons PR Newswire A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seas...